51 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
whether the equity incentive awards that replaced the existing options were of equivalent value, the options will be cancelled and holders will continue … holding the awards for which the options were replaced. If outstanding options are not replaced by another form of equity incentive award
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
:
The Company’s Long-Term Incentive Plan (the “Plan”);
The Company’s Supplementary Long-Term Incentive Plan (the “Supplementary Plan”);
The Company’s … Share Award.
Long Term Incentive Plans
The Plans are equity-settled, and the Company may grant various forms of equity awards, including the granting
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
of death or disability. In the event of a change of control, the Compensation Committee will determine whether the equity incentive awards that replaced … replaced. If outstanding options are not replaced by another form of equity incentive award, or are replaced by awards that the Compensation Committee
424B3
NAMS
NewAmsterdam Pharma Company NV
19 Apr 24
Prospectus supplement
4:21pm
;
116,971 Ordinary Shares reserved for issuance pursuant to future awards under the Company’s Long-Term Incentive Plan;
63,922 Ordinary Shares reserved … to future awards under the Company’s Supplementary Long-Term Incentive Plan; and
1,886,137 Ordinary Shares issuable upon the achievement of a certain
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
Shares reserved for issuance pursuant to future awards under the Company’s Long-Term Incentive Plan;
63,922 Ordinary Shares reserved for issuance … the Company’s Supplementary Long-Term Incentive Plan; and
1,886,137 Ordinary Shares issuable upon the achievement of a certain clinical development
10-K
EX-10.8
ocv5xc9nlaumx yuk
28 Feb 24
Annual report
8:00am
10-K
EX-10.7
sy0deh
28 Feb 24
Annual report
8:00am
10-K
r2reatn
28 Feb 24
Annual report
8:00am
10-K
EX-97.1
w6f8m h8lw50
28 Feb 24
Annual report
8:00am
10-K
EX-10.9
iodkty dujsjay7
28 Feb 24
Annual report
8:00am
10-K
EX-10.10
9fp1 eers
28 Feb 24
Annual report
8:00am
10-K
EX-10.4
angic
28 Feb 24
Annual report
8:00am
424B5
g9dzbusjruo93 lnz
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
a8av0o6fhrjuy 7l
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
zo4x8g3edgsav6dfd h1
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
424B3
0wl0uz yh4hxn
19 Dec 23
Prospectus supplement
4:36pm
F-3
4sn0f
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-1.2
33o43vtzj
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
b84chsujlkf6
15 Aug 23
Prospectus supplement
4:52pm
POS AM
1u1a31
7 Aug 23
Prospectus update (post-effective amendment)
7:56am